AUTHOR=Liu Hongyan , Ma Yanpin , Chen Wenjuan , Gu Xinyu , Sun Jiachun , Li Penghui TITLE=Strategies for the drug development of cancer therapeutics JOURNAL=Frontiers in Pharmacology VOLUME=Volume 16 - 2025 YEAR=2025 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1656012 DOI=10.3389/fphar.2025.1656012 ISSN=1663-9812 ABSTRACT=Cancer is a global health threat, with its treatment modalities transitioning from single therapies to integrated treatments. This paper systematically explores the key technological systems in modern cancer treatment and their application value. Modern cancer treatment relies on four core technological pillars: omics, bioinformatics, network pharmacology (NP), and molecular dynamics (MD) simulation. Omics technologies integrate various biological molecular information, such as genomics, proteomics and metabolomics, providing foundational data support for drug research. But the differences in data and the challenges of integrating it often lead to biased predictions, and that’s a big limitation for this technology. Bioinformatics utilizes computer science and statistical methods to process and analyze biological data, aiding in the identification of drug targets and the elucidation of mechanisms of action. It is important to note that the prediction accuracy largely depends on the algorithm chosen. Consequently, this dependence may affect the reliability of the research results. NP, based on systems biology, studies drug-target-disease networks, revealing the potential for multitargeted therapies. That said, this method may overlook important aspects of biological complexity, such as variations in protein expression. This oversight can lead to overestimating the effectiveness of multi-targeted therapies, resulting in false positives in efficacy assessments, which somewhat limits its practical usefulness. MD simulation examines how drugs interact with target proteins by tracking atomic movements, thus enhancing the precision of drug design and optimization. Nevertheless, this technology faces practical challenges, such as high computational costs and sensitivity of model accuracy to the parameters of the force field. The synergistic application of these technologies significantly shortens the drug development cycle and promotes precision and personalization in cancer therapy, bringing new hope to patients for successful treatment. However, researchers still face challenges like the variability of data. Future efforts need to use Artificial Intelligence (AI) to establish standardized data integration platforms, develop multimodal analysis algorithms, and strengthen preclinical-clinical translational research to drive breakthrough advancements in cancer treatment. With the ongoing technological improvements, the vision of personalized medicine—tailored treatments based on individual patient characteristics—will gradually be realized, significantly enhancing treatment efficacy and improving patients’ quality of life.